Your cart is currently empty!.
You may check out all the available products and buy some in the shop.
Continue Shopping
Johnson & Johnson (JNJ) (Q1FY25) – Focused innovation and resilient growth
Highlights of the report
In MedTech, sales grew 4.1%, driven by strong results from Abiomed, Shockwave, surgical vision, and wound closure. Important milestones included the upgrade of Impella’s clinical guidelines and the launch of
Shockwave’s new device for peripheral artery disease
CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.
CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).
Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.
Sales in the US have grown by 6% in Q1FY25 to $12.3bn from $11.62bn in Q1FY24. Whereas in FY24 sales increased by 8.31% to $50.3bn from $46.4bn in the last year’s same period.
Johnson & Johnson in the last 3 months, the stock has given a return of 6%, the stock price increased to $154.93 as of Apr 24, 2025, from $146.82 as of Jan 24, 2025.
Executive Summary
• CrispIdea Forecast
– Income Statement
– Balance Sheet
– Cash Flow
– Common Size Ratio Analysis
– CrispIdea Segment Forecast
• Valuation & Historical Performance
– P/E Analysis
– CrispIdea Valuation
– Peer Comparison
– Ratio Analysis
– Economic Value-Added Analysis
– Du Pont Analysis
– CrispIdea Forecast Relative to Consensus
– Consensus Momentum
– Segment Performance
– Key Developments
– M&A Deals
• Ownership
• Stock Price Performance
• Crispidea Coverage
https://www.crispidea.com/report/johnson-johnson-equity-report-q4-24/
Report details
Johnson & Johnson (JNJ) (Q1FY25) – Focused innovation and resilient growth
- Pages
- 30
- Format
- Language
- english
- Released
- May 1, 2025
- Last Updated
- May 1, 2025
Price
$240.00
Company Reports
- August 7, 2026
Mondelez International (Q2FY26)- Emerging Markets remained the company's strongest growth engine in Q2FY26, with organic revenue increasing 4.4%, supported by strong volume and mix performance across most snacking categories.
$240.00
- August 7, 2026
Hewlett Packard Enterprise delivered one of its strongest quarters as enterprise demand accelerated across networking, Cloud & AI, storage, and hybrid cloud.
$224.00
- August 7, 2026
Okta Inc Q1FY27 - Okta continues to strengthen its position within large enterprise customers, which remains the primary driver of recurring revenue growth.
$240.00
- August 7, 2026
UiPath is successfully evolving from a traditional RPA provider into an enterprise AI and process orchestration platform.
$240.00
Sector Reports
- August 7, 2026
As we approach 2026, the APAC region continues to stand out as a global growth engine. But for the institutional investor, the real “investment season” is happening right now.
$350.00
- August 7, 2026
Semiconductors remain vital to modern electronics, powering devices like smartphones, tablets, and PCs. While the industry has recovered from pandemic disruptions, it now faces geopolitical tensions, regulatory shifts, and supply chain diversification efforts.
$1,450.00
- August 7, 2026
Tokenization is reshaping how financial assets are issued, settled, and stored. The technology is proven, regulations are advancing, and major asset managers are already moving capital onto blockchain-based systems.
$230.00
- August 7, 2026
Asia-Pacific (APAC) region is dominant in the global humanoid robot market, accounting for 36.52% of worldwide market share in 2026. With more than one-third of the global market, Asia-Pacific has established itself as the leading region in humanoid robotics adoption, development, and production.
$300.00
